# A Study of Degarelix in Taiwanese Patients With Prostate Cancer

> **NCT01220869** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 110 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT01220869
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01220869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01220869, "A Study of Degarelix in Taiwanese Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01220869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*